Madrigal Pharmaceuticals, Inc. vs Abbvie Inc.
MDGL vs ABBV — side-by-side comparison from reported financials. MDGL leads 3, ABBV leads 6 of 9 comparable metrics.
Madrigal Pharmaceuticals, Inc.
MDGL · Healthcare
$471.75-1.08%Strong
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
| Metric | MDGL | ABBV |
|---|---|---|
| Price | $471.75 | $276.43 |
| Market cap | $10.9B | $488B |
| Revenue (TTM) | $1.28B | $64.4B |
| Revenue growth | +149.0% | +1.8% |
| Net margin | -25.3% | 9.8% |
| Free cash flow | -$207M | $18.2B |
| Net cash (debt) | $644M | ($56.2B) |
| 1-year price return | +10.1% | +19.8% |
| P/E | — | 77.4 |
| P/E vs own history (cheap-side %) | — | 23% |
| Dividend yield | — | 2.45% |
| Return on equity | -57% | 96% |
| Altman Z-score | 7.49 | 2.33 |
| CV checks passed | 5 of 9 | 9 of 9 |
| Employees | 915 | 57,000 |
Full résumé-style profiles: MDGL CV · ABBV CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.